PMID- 10710206
OWN - NLM
STAT- MEDLINE
DCOM- 20000420
LR  - 20061115
IS  - 0889-2229 (Print)
IS  - 0889-2229 (Linking)
VI  - 16
IP  - 3
DP  - 2000 Feb 10
TI  - A randomized trial of interferon alpha therapy for HIV type 1 infection.
PG  - 183-90
AB  - The immunologic and virologic efficacy and safety of interferon a (IFN-alpha) 
      administered in combination with zidovudine (ZDV) and zalcitabine (ddC) was 
      evaluated in HIV-infected subjects with CD4+ cell counts between 300 and 500 
      cells/ml and no more than 14 weeks of prior antiretroviral therapy. A total of 
      256 subjects enrolled in an open-label, randomized controlled trial. Subjects 
      were randomized equally into treatment groups. All subjects received ZDV and ddC, 
      while half also receive IFN-alpha (3 MU subcutaneously every 24 hr). At 48 weeks 
      the median average area under the curve minus baseline (AAUCMB) for plasma HIV-1 
      RNA for the two-drug group was -0.68 versus -0.75 log10 copies/ml for the 
      IFN-alpha group (p = 0.046). Mean HIV-1 RNA changes from baseline to 48 weeks for 
      these groups were -0.65 and -1.12 log10 copies/ml, respectively (p = 0.010). The 
      median AAUCMB for CD4+ cell count for the two-drug group was 28 versus -1 
      cells/mm3 for the IFN-alpha group (p = 0.011). Neutropenia, anemia, and drug 
      intolerance were more common in the IFN-alpha group. This study demonstrates that 
      IFN-alpha inhibits HIV-1 replication but attenuates the CD4+ cell response to 
      dual therapy with ZDV and ddC.
FAU - Haas, D W
AU  - Haas DW
AD  - Vanderbilt University Medical Center, Nashville, Tennessee 37212, USA. 
      david.w.haas@vanderbilt.edu
FAU - Lavelle, J
AU  - Lavelle J
FAU - Nadler, J P
AU  - Nadler JP
FAU - Greenberg, S B
AU  - Greenberg SB
FAU - Frame, P
AU  - Frame P
FAU - Mustafa, N
AU  - Mustafa N
FAU - St Clair, M
AU  - St Clair M
FAU - McKinnis, R
AU  - McKinnis R
FAU - Dix, L
AU  - Dix L
FAU - Elkins, M
AU  - Elkins M
FAU - Rooney, J
AU  - Rooney J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
RN  - 0 (Anti-HIV Agents)
RN  - 0 (HIV Core Protein p24)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-HIV Agents/adverse effects/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Drug Resistance, Microbial
MH  - Female
MH  - HIV Core Protein p24/blood
MH  - HIV Infections/blood/*drug therapy/immunology/virology
MH  - *HIV-1
MH  - Humans
MH  - Interferon-alpha/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - RNA, Viral/blood
EDAT- 2000/03/10 09:00
MHDA- 2000/04/25 09:00
CRDT- 2000/03/10 09:00
PHST- 2000/03/10 09:00 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 2000/03/10 09:00 [entrez]
AID - 10.1089/088922200309278 [doi]
PST - ppublish
SO  - AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):183-90. doi: 
      10.1089/088922200309278.